First, we sought to determine whether there is diurnal variation in hemostatic factors related to thrombogenesis and hypercoagulability among patients with chronic atrial fibrillation (AF). Second, we sought to determine whether levels of soluble thrombomodulin (sTM), a marker of endothelial function, or soluble P-selectin (sP-sel), an index of platelet activation, are altered in patients with AF as compared with subjects in sinus rhythm.
Atrial fibrillation (AF) is a common cardiac arrhythmia and is associated with a substantial risk of stroke and thromboembolism (1) . This is probably because AF confers a hypercoagulable state, with abnormalities of hemostasis, thrombosis and platelet function (2) (3) (4) . For example, in a cross-sectional study of 73 patients with chronic AF and 21 patients in sinus rhythm, Kumagai et al. (4) reported increased fibrin D-dimer levels, a marker of intravascular thrombogenesis, irrespective of the presence of underlying heart disease. The beneficial role of oral anticoagulation therapy in reducing the risk of stroke and thromboembolic in patients with nonvalvular AF has been confirmed by recent large-scale studies (5) .
Recent research has identified two more plasma markers that may be of use in understanding the pathophysiology of thrombogenesis. Soluble thrombomodulin (sTM), another marker of endothelial cell damage, is increased in patients with systemic hypertension, peripheral artery disease and coronary artery disease, and raised levels predict adverse events even among patients receiving long-term anticoagulation (6 -9) . It has been suggested that increased levels of the soluble adhesion molecule, P-selectin, implies platelet activation (10, 11) , as may be the case in atherosclerosis, hypertension and thrombotic consumptive disorders (12) (13) (14) .
Many variables within biophysical systems, such as the onset of acute vascular events, show peaks and troughs in the course of a 24-h period (15) (16) (17) (18) (19) . For example, prominent clustering of cardiovascular events, such as acute myocardial infarction, between 6 AM and 12 PM has been demonstrated (20 -23) . Many such events have thrombosis as an underlying pathologic process, and some hemostatic factors have also been shown to demonstrate a circadian variation that may in part contribute to this diurnal incidence (24 -26) . Furthermore, paroxysmal AF, which is also associated with a risk of stroke, exhibits a unique circadian variation that differs from the well-known pattern in acute cardiovascular events (27) . As the mechanisms of the increased thromboembolic risk in patients with AF have not been fully elucidated, abnormalities in indexes of hypercoagulability indicative of a prothrombotic state could account for this risk (1) (2) (3) (4) 28, 29) , which may demonstrate diurnal variation.
It is unclear whether there is diurnal variation in these hemostatic factors related to thrombogenesis and hypercoagulability in patients with chronic AF that may perhaps relate to the occurrence of clinical events. It has also not yet been determined whether levels of sTM or soluble P-selectin (sP-sel) are altered in patients with AF as compared with subjects in sinus rhythm. The aim of the present study was to test both these hypotheses prospectively.
METHODS
Patients and control subjects. We recruited patients with chronic AF, which was seen on the electrocardiogram on at least two occasions at least six weeks apart, either by a general practitioner or at hospital or outpatient clinic review. Exclusion criteria were other acute causes of AF (e.g., thyrotoxicosis, pneumonia), acute cardiovascular or cerebrovascular events (e.g., myocardial infarction, congestive heart failure, stroke), use of aspirin or anticoagulant agents, inflammatory or connective tissue disease and chronic renal or hepatic disease. A random subgroup of 20 patients was admitted for 36 h for clinical assessment before initiation of anticoagulation therapy. Five venous blood samples were collected through an indwelling cannula at 6-h intervals from 12 PM to 12 PM the following day.
Control subjects were found among the healthy hos- Power calculation and statistics. Data were initially analyzed by using the Shapiro-Wilks test to determine normality of distribution. In the cross-sectional study, data for vWf, sTM and fibrinogen are presented as the mean value Ϯ SD and analyzed by using the unpaired t test; however, sP-sel levels were nonparametrically distributed and expressed as the median value with interquartile range and analyzed using the Mann-Whitney U test. Correlations between indexes were performed by the Spearman rank correlation method. We hypothesized that sP-sel and sTM would be increased by one-half of a standard deviation among patients with AF as compared with control subjects.
To prove this, we would need to recruit a minimum of 40 patients and 40 control subjects for a one-sided p value Ͻ0.05 with 80% power. Two other studies of diurnal variation recruited only 9 and 10 subjects, respectively (24, 25) . Therefore, we aimed to recruit at least 20 subjects.
In the diurnal study, the results were analyzed by repeated measures analysis of variance. 
RESULTS
Cross-sectional data. Demographic data are presented in Table 1 . There were no differences in age, gender, proportion of current smokers or blood pressure between the groups. Patients with AF had higher plasma sP-sel, sTM, fibrinogen and vWF levels as compared with control subjects in sinus rhythm (Table 2 ). There were no significant differences for the measured levels of plasma sP-sel, sTM, vWF and fibrinogen between patients with lone AF (n ϭ 16) and patients with AF associated with underlying disease (n ϭ 36) ( Table 2) .
Correlations with clinical variables. Among patients with AF, there was a significant correlation between plasma fibrinogen and sP-sel levels (r ϭ 0.567 [Spearman], p Ͻ 0.001). Among the control subjects, the correlation between plasma fibrinogen and sP-sel was also significant (r ϭ 0.334, p ϭ 0.016). There were no other significant correlations between various indexes in patients or control subjects.
Diurnal study. We studied 20 patients with chronic AF who were not receiving antithrombotic therapy. Demographic data for these patients are summarized in Table 3 . Data are presented as the mean value Ϯ SD (analyzed by the unpaired t test), except for soluble P-selectin levels, which are expressed as the median value (interquartile range), analyzed using the Mann-Whitney U test. AF ϭ atrial fibrillation.
There was no significant diurnal variation in plasma levels of sP-sel, sTM, vWF or fibrinogen over the five sampling points (12 PM, 6 PM, 12 AM, 6 AM and 12 PM) over the 24-h period (Table 4) .
DISCUSSION
In the present study, we confirmed previous observations of increased vWF and fibrinogen levels in patients with chronic AF as compared with healthy control subjects in sinus rhythm (2), and we provide new evidence of a hypercoagulable or thrombogenic state in chronic AF, with increased levels of the endothelial cell product, sTM, as well as a new marker of platelet activation-soluble adhesion molecule P-selectin. Importantly, this hypercoagulable state does not appear to be subject to any significant diurnal variation, nor is it related to whether or not the patient had lone AF or not, suggesting that chronic AF confers a constant prothrombotic state per se over the 24-h day, which was independent of underlying heart disease or etiology (3).
Endothelial dysfunction in AF.
The increase in vWF levels parallels the increased levels of sTM, another index of endothelial dysfunction (6,30 -32) . The latter molecule is of interest because thrombomodulin is a constitutive membrane protein that is an important regulator of activated thrombin, converting thrombin from a procoagulant (cleaving fibrinogen) to an anticoagulant by altering its substrate specificity, so that it activates protein C (30). However, thrombomodulin probably needs to be cleaved for soluble forms to be found in the circulation. In vitro experiments suggest that the presence of sTM in tissue culture supernatant is probably the result of damage to the endothelial cells (31) . Unlike vWF, however, levels of sTM appear to be independent of the inflammatory cytokines interleukin-1 and tumor necrosis factor (6, 32) . Our finding of high sTM levels in patients with chronic AF in the present study is in contrast to a recent preliminary report from a much smaller cohort of patients with chronic AF in whom this marker may not have been elevated (33) . The precise mechanism for the increased markers of endothelial dysfunction or activation in cardiovascular disorders is uncertain, but may nevertheless include a cytokine-mediated increase in synthesis, increased secretion from stored pools, increased synthesis de novo or release from damaged endothelial cells. In the case of AF, abnormalities in blood flow may be partly responsible, resulting in flow abnormalities and adding to endothelial disturbance in the pulmonary vasculature.
Platelet activation in AF.
The presence of platelet activation has been recognized in chronic AF, which has usually been indicated by high plasma levels of betathromboglobulin (28) , although this finding is controversial (34, 35) . In the present study, we have measured levels of sP-sel, which is a new marker of platelet activation (10, 11) . Our sP-sel data therefore complement those of Pongratz et al. (35) , who found increased expression of membranebound P-selectin on platelets of patients with AF. Like Pongratz et al. (35), we interpret this as further evidence of inappropriate platelet activation in these patients, which is correlated with plasma fibrinogen, an established index of hemorheology and clotting. Increased platelet activation, in combination with endothelial dysfunction and abnormal hemostatic factors, is thus in keeping with the hypercoagulable state in AF (3,4). (17), we are not aware of any published studies specifically investigating whether there is a diurnal variation in stroke onset among patients with AF. Nevertheless, preliminary observations from an ongoing project in our unit do not suggest a significant diurnal pattern to the onset of stroke in patients with AF. The absence of a diurnal variation in the hypercoagulable state in patients with AF would be in keeping with this.
Clinical study implications.
Although the use of antithrombotic therapy may reduce the risk of thrombosis, even administration of anticoagulation with a constant infusion of intravenous heparin is associated with a diurnal variation in the intensity of anticoagulation (36) . If chronic AF did show significant diurnal variation in the hypercoagulable or prothrombotic state, there will be periods when anticoagulation intensity may be insufficient to provide prophylaxis against thromboembolism, and other periods when anticoagulation exceeds that needed therapeutically, with a corresponding increase in the risk of bleeding. These problems are highly clinically relevant when considering thromboprophylaxis for patients with AF. Our finding of a constant hypercoagulable state in chronic AF, therefore, provides further reassurance that anticoagulation with warfarin, aiming for a consistent target International Normalized Ratio of 2.0 to 3.0, is likely to provide adequate anticoagulation "cover" for each 24-h period.
Study limitations. This study is limited by its casecontrolled, cross-sectional design and the association of AF with other pathologic processes, such as hypertension and coronary artery disease, or risk factors for atherosclerosis. It has previously been shown that the hypercoagulable state in AF is independent of underlying etiology or associated heart disease (2-4). In addition, hypertension and coronary artery disease would result in relatively smaller changes in these markers as compared with those seen in the present study of AF. However, the main objective of our study was to assess the circadian or diurnal variation in the hypercoagulable state in AF, rather than to reproduce many previous analyses of the effects of heart disease on the markers of hypercoagulability, which are suggestive of a continuum that exists between health, "statistically" increased hemostatic abnormalities as a prethrombotic or hypercoagulable state and "overtly" increased clotting in acute thrombosis (or sometimes in acute extravascular fibrin formation) which follows injury or operation (2-4). We also accept that the present study was neither designed nor adequately powered to specifically compare differences in the hypercoagulable state between patients with lone AF and patients with AF associated with underlying disease; however, previous data (3) suggest that the hypercoagulable state in AF is independent of underlying etiology and structural heart disease.
Conclusions.
We suggest that there is no circadian or diurnal variation in the hypercoagulable state seen in AF, as assessed by plasma fibrinogen and markers of platelet (sP-sel) and endothelial function (vWF and sTM). The persistent hypercoagulable state, together with the loss of diurnal variation in various hemostatic markers, in chronic AF may contribute in part to the high risk of stroke and thromboembolic complications in these patients.
